摘要
目的探讨乌司他丁单药与联合低分子肝素治疗高脂血症性急性胰腺炎的效果及对CRP的影响.方法选取2020年1月-2021年2月收治的高脂血症性急性胰腺炎患者106例,收集临床资料开展此研究,依照药物干预方案的差异分为两组.对照组给予乌司他丁单药治疗,研究组给予乌司他丁联合低分子肝素治疗.对比两组疗效、炎症指标水平以及两组指标恢复及临床症状缓解时间.结果研究组总有效率高于对照组(P<0.05);药物干预前两组患者D-二聚体水平及CRP水平均无明显区别(P>0.05),经治疗干预两组上述指标水平均改善,研究组患者以上各指标水平均低于对照组(P<0.05);研究组患者各项实验室指标恢复时间及临床症状改善时间均比对照组更短(P<0.05).结论将乌司他丁联合低分子肝素方案用于治疗高脂血症性急性胰腺炎,可促进患者疗效提升,改善炎症指标水平,促进临床检验指标及临床症状恢复,值得应用.
Objective To investigate the effect of ulinastatin alone and combined twhi low molecular weight heparin in the treatment o f hyperlipidemic acute pancreatitis and its effect on CRPM.ethods 106 patients with hyperlipidemic pancreatitis treated in ouro shpital from January 2020 to February 2021 were selected.The clinical data erwe collected to carry out this study.They were divided into ot wgroups according to the difference of drug intervention scheme.The ctornol group was treated with ulinastatin alone,and the study gurpo was treated with ulinastatin combined with low molecular weight heparin.Th ecurative effect,inflammatory index level,index recovery and cilnical symptom relief time of the two groups were compareRde.sults The total effective rate of the study group was higher thana tt hof the control group(P<0.05);before drug intervention,there was no significant diffeernce in the levels of D-dimer and CRP between the two groupPs>(0.05).After treatment intervention,the levels of the above inxdes in the two groups were improved,and the levels of the ab oviendexes in the study group were lower than those in the control groupP<(0.05);the recovery time of various laboratory indexes and thiem provement time of clinical symptoms in the study group were shorter than tho sien the control group P(<0.05).Conclusion Ulinastatin combined with low molecular weight heparin in the treatment of hyperlipidemic atceu pancreatitis can promote the curative effect of patients,irmopve the level of inflammatory indicators,and promote the recovery of clinica ltest indicators and clinical symptoms.It is worthy of applicaiton.
作者
吴林
孔晓霞
郑桂贞
Wu Lin;Kong Xiaoxia;Zheng Guizhen(Department of Gastroenterology,Shantou Central Hospital,Shantou,Guangdong 515031,China;Department of Gynecological Oncology,Affiliated Tumor Hospital of Shantou University Medical College,Shantou,Guangdong 515031,China)
出处
《首都食品与医药》
2022年第18期77-79,共3页
Capital Food Medicine
基金
汕头市科技计划医疗卫生类别项目(项目编号:191221235263433)。